)
Edge15 May 2026
TOMRA: Closing the Loop
The story of TOMRA: from reverse vending machine pioneer to global technology for deposit systems, recycling, and resource optimization.
Catalyst Pharmaceuticals
Catalyst Pharmaceuticals (CPRX) investor relations material
Catalyst Pharmaceuticals Proxy filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Proxy filing summary12 May, 2026
Executive summary
Announced agreement for acquisition by Angelini Pharma, with closing expected in Q3 2026.
First quarter 2026 revenues reached $149.4 million, a 28.2% year-over-year increase, driven by FIRDAPSE and AGAMREE.
Integration planning with Angelini Pharma is underway, with both companies operating independently until closing.
Employees are encouraged to maintain business as usual during the transition period.
Forward-looking statements highlight expectations, integration plans, and potential risks related to the transaction.
Voting matters and shareholder proposals
Shareholders will be asked to approve the merger with Angelini Pharma, as detailed in the forthcoming proxy statement.
Proxy materials will be distributed to security holders, urging them to review all documents before voting.
Board of directors and corporate governance
Directors and executive officers of both companies may participate in the proxy solicitation.
Information on directors’ and officers’ interests will be disclosed in the proxy statement and recent annual filings.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Catalyst Pharmaceuticals
- Q1 2026 saw revenue and net income growth, strong cash, and a major merger announcement.CPRX
Q1 202611 May 2026 - Angelini Pharma acquires Catalyst for $4.1B, expanding in brain health and rare diseases.CPRXProxy filing8 May 2026
- Angelini Pharma to acquire for $31.50/share in cash, creating a global rare disease platform.CPRXProxy filing8 May 2026
- Angelini Pharma to acquire all shares for $31.50 each in a $4.1B cash deal, closing Q3 2026.CPRXProxy filing7 May 2026
- 2025 revenues rose 19.8% to $589M, with double-digit growth and profitability forecast for 2026.CPRXQ4 20258 Apr 2026
- Strong growth in rare disease portfolio, robust cash, and strategic expansion plans for 2026.CPRXBarclays 28th Annual Global Healthcare Conference10 Mar 2026
- Q2 revenue up 23.2% to $122.7M, with strong Agamree launch and patent wins boosting outlook.CPRXQ2 20242 Feb 2026
- Portfolio expansion, robust financials, and global growth position the company for long-term success.CPRXJefferies 2024 Global Healthcare Conference1 Feb 2026
- Firdapse and Agamree drive growth, with global expansion and portfolio diversification underway.CPRX2024 Wells Fargo Healthcare Conference22 Jan 2026
Next Catalyst Pharmaceuticals earnings date
Q2 20266 Aug, 2026
Catalyst Pharmaceuticals
Next Catalyst Pharmaceuticals earnings date
Q2 20266 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage